2. Academic Validation
  3. Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors

Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors

  • J Immunother Precis Oncol. 2023 Feb 2;6(2):91-102. doi: 10.36401/JIPO-22-27.
Zainab Fatima 1,  Abdulrahman Abonofal 2,  Bettzy Stephen 3
Affiliations

Affiliations

  • 1 Department of Hospice and Palliative Care, Virginia Commonwealth University, Richmond, VA, USA.
  • 2 Department of Medicine, Section of Hematology/Oncology, West Virginia University, Morgantown, WV, USA.
  • 3 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
PMID: 37214204 DOI: 10.36401/JIPO-22-27
Abstract

Immune checkpoint inhibitors have revolutionized the treatment paradigm of several cancers. However, not all patients respond to treatment. Tumor cells reprogram metabolic pathways to facilitate growth and proliferation. This shift in metabolic pathways creates fierce competition with immune cells for nutrients in the tumor microenvironment and generates by-products harmful for immune cell differentiation and growth. In this review, we discuss these metabolic alterations and the current therapeutic strategies to mitigate these alterations to metabolic pathways that can be used in combination with checkpoint blockade to offer a new path forward in Cancer management.

Keywords

adenosine pathway; amino acid metabolism; glucose metabolism; immune checkpoint inhibitors; lipid metabolism.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99169
    99.35%, CD73 Inhibitor